Provided by Tiger Trade Technology Pte. Ltd.

Rigel Pharmaceuticals

49.20
+1.703.58%
Volume:93.93K
Turnover:4.55M
Market Cap:919.05M
PE:2.99
High:49.20
Open:48.00
Low:47.73
Close:47.50
52wk High:52.24
52wk Low:24.95
Shares:18.68M
Float Shares:14.85M
Volume Ratio:0.47
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):16.45
EPS(LYR):19.48
ROE:126.90%
ROA:14.95%
PB:2.16
PE(LYR):2.53

Loading ...

Rigel Appoints Board Member Alison L. Hannah, M.d. as Chief Medical Officer

THOMSON REUTERS
·
Jul 01

Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU

Reuters
·
Jun 18

Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment

TIPRANKS
·
Jun 17

Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu

MT Newswires Live
·
Jun 17

Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline priorities

Reuters
·
Jun 17

Rigel closes license agreement for Veppanu

TIPRANKS
·
Jun 17

BRIEF-Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)

Reuters
·
Jun 17

Rigel closes VEPPANU license deal, makes USD 70 million upfront payment

Reuters
·
Jun 17

Rigel Announces Closing of Licensing Agreement for Veppanu™ (Vepdegestrant)

THOMSON REUTERS
·
Jun 17

Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 02

Rigel Pharma director Kamil Ali-Jackson disposes of 2,500 common shares worth $72,925

Reuters
·
May 29

Knight Therapeutics launches Tavalisse in Mexico for chronic immune thrombocytopenia

Reuters
·
May 28

Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
May 27

Rigel CEO to Present Company Overview at Jefferies Global Healthcare Conference

Reuters
·
May 27

Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
May 22

Rigel says Phase 3 AcceleRET-Lung trial meets primary endpoint for GAVRETO in NSCLC

Reuters
·
May 22

Rigel Announces Oral and Poster Presentations at the 2026 Asco Annual Meeting and Eha2026 Congress

THOMSON REUTERS
·
May 22

Rigel Pharmaceuticals shareholders approve amended 2018 equity incentive plan

Reuters
·
May 21

Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead

Simply Wall St.
·
May 20

Rigel Pharmaceuticals Highlights Growth Amid Rising Costs

TIPRANKS
·
May 20